Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research note issued on Wednesday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Shares of NASDAQ ADXS opened at $0.03 on Wednesday. The business has a 50-day moving average of $0.03 and a 200-day moving average of $0.04. The stock has a market capitalization of $1.22 million, a price-to-earnings ratio of 0.00 and a beta of 1.62. Ayala Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $1.49.

About Ayala Pharmaceuticals

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.